Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07688369
PHASE1

Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults

Sponsor: Serum Institute of India Pvt. Ltd.

View on ClinicalTrials.gov

Summary

The primary purpose of this study is to test a new experimental recombinant Poliomyelitis vaccine (rPV) in comparison to the commercially available inactivated poliovirus vaccine. The design of the study is double-blinded, randomised and active controlled. The active controlled product is considered the commercially available vaccine (IPOL).

Official title: A Phase 1, Double-blinded, Randomised, Active Controlled, Clinical Trial to Assess the Reactogenicity, Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

36

Start Date

2026-07

Completion Date

2027-03

Last Updated

2026-07-07

Healthy Volunteers

Yes

Conditions

Interventions

BIOLOGICAL

Recombinant Poliomyelitis Vaccine (rPV)

Recombinant Poliomyelitis Vaccine (VLP) is manufactured by Serum Institute of India Pvt. Ltd.

BIOLOGICAL

Inactivated Poliomyelitis Vaccine (IPOL)

IPOL (inactivated poliovirus vaccine) is a marketed Sanofi

Locations (1)

Doherty Clinical Trials Limited

East Melbourne, Victoria, Australia